Difficulties in understanding the mechanisms of HIV neuropathogenesis include the inability to study dynamic processes of infection, cumulative effects of the virus, and contributing host immune responses. We used $^1$H magnetic resonance spectroscopy and studied monocyte activation and progression of CNS neuronal injury in a CD8 lymphocyte depletion model of neuroAIDS in SIV-infected rhesus macaque monkeys. We found early, consistent neuronal injury coincident with viremia and SIV infection/activation of monocyte subsets and sought to define the role of plasma virus and monocytes in contributing to CNS disease. Antiretroviral therapy with essentially non–CNS-penetrating agents resulted in slightly decreased levels of plasma virus, a significant reduction in the number of activated and infected monocytes, and rapid, near-complete reversal of neuronal injury. Robust macrophage accumulation and productive virus replication were found in brains of infected and CD8 lymphocyte–depleted animals, but no detectable virus and few scattered infiltrating macrophages were observed in CD8 lymphocyte–depleted animals compared with animals not receiving antiretroviruses that were sacrificed at the same time after infection. These results underscore the role of activated monocytes and monocyte infection outside of the brain in driving CNS disease.
Magnetic resonance spectroscopy reveals that activated monocytes contribute to neuronal injury in SIV neuroAIDS

Kenneth Williams,1,2 Susan Westmoreland,1,3 Jane Greco,1,4 Eva Ratai,1,4 Margaret Lentz,1,4 Woong-Ki Kim,1,2 Robert A. Fuller,1,4 John P. Kim,1,4 Patrick Autissier,1,2 Prahat K. Sehgal,1,3 Raymond F. Schinazi,5 Norbert Bischofberger,6 Michael Piatak Jr.,7 Jeffrey D. Lifson,7 Eliezer Masliah,8 and R. Gilberto González1,4

1Harvard Medical School, Boston, Massachusetts, USA. 2Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. 3Neuroradiology Division and Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, Massachusetts, USA. 4Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine/Veterans Affairs Medical Center, Atlanta, Georgia, USA. 5Gilead Sciences, Foster City, California, USA. 6AIDS Vaccine Program, Science Applications International Corporation Frederick Inc., National Cancer Institute at Frederick, Frederick, Maryland, USA. 7Neurosciences Department, UCSD, La Jolla, California, USA.

Introduction

Nearly one-third of HIV-infected individuals develop neurological symptoms ranging from minor cognitive impairment to severe dementia. Neurological deficits are related to neuronal injury and loss; however, the mechanisms of injury are poorly understood. Because the virus does not directly infect neurons, indirect mechanisms are likely operative (1). Observations in HIV-infected humans and SIV-infected animals underscore the role of the immune system in contributing to CNS disease (2–5). Expansion of monocyte subsets, some of which are activated, correlates with the incidence of HIV-associated dementia (HAD) and other CNS diseases without known viral etiology (6–11). Emerging evidence in rodents and humans points to monocyte subsets including CD14+CD16- cells that are actively recruited to inflammatory sites and CD14+CD16+ cells that traffic to noninflamed tissues (12). Studies of cytokine production and viral infection suggest differential activation of monocyte populations as well as differential susceptibility to infection (12–14). Activated CD8+ T lymphocytes in blood, cerebrospinal fluid (CSF), and the CNS parenchyma are detected in infected individuals and animals at sites where they are thought to contribute to neurophysiological abnormalities and perhaps control monocyte accumulation in the CNS (3, 15–17). In addition, levels of chemokines regulating monocytes/macrophage and T cell traffic are elevated in the CSF with HIV and SIV infection and correlate with the incidence of HAD (18, 19). These observations support the putative role of activated monocytes and CD8+ T lymphocytes in regulating HIV-induced CNS disease (20).

Obstacles to precisely defining immune system contribution to CNS disease include the inability to assay neuronal injury longitudinally and the sporadic nature and low incidence of HAD. Not knowing when and how long individuals are infected adds another level of uncertainty. Advances in noninvasive neuroimaging using1H magnetic resonance spectroscopy (MRS) allow for the detection of brain abnormalities prior to the onset of neurological symptoms. Such studies can also measure reversal of abnormalities with antiretroviral therapy (21–25).

SIV, like HIV, infects CD4+ T lymphocytes, blood monocytes/macrophages, and brain macrophages (26–28). The SIV-infected macaque model of neuroAIDS best recapitulates HIV neuropathogenesis; but similar to the situation in HIV-infected humans, the low percentage (~25%) of animals developing SIV encephalitis (SIVE) and the prolonged progression (1–3 years) to the devel-
opment of AIDS somewhat limit its usefulness (29). Recently, 2 accelerated macaque models that have rapid disease progression and high incidence of SIVE have been reported (30–33). One uses 2 viruses that result in CD4+ T lymphocyte depletion and highly efficient replication in CNS macrophages (30, 34). The other uses mAb-mediated depletion of CD8 lymphocytes, which results in accumulation of monocytes/macrophages in the CNS early after infection, rapid disease progression, and severe SIVE (31–33). Both models underscore a role of the peripheral immune system in controlling the rate and severity of CNS disease progression (2, 16).

Here we report marked and consistent neuronal injury, as assessed by decreased N-acetylaspartate (NAA) levels detected by in vivo 1H MRS, in SIV-infected and CD8 lymphocyte–depleted animals. Such injury occurs over a short time and is highly reproducible in persistently CD8 lymphocyte–depleted animals. Histopathologic examination revealed significant accumulation in CNS of perivascular macrophages, SIV protein, multinucleated giant cells (MNGCs), glial cell activation, and neuronal injury. Flow cytometric analysis demonstrated an expansion of a population of activated monocytes with viremia coinciding with decreased NAA that subsides and then reemerges with the onset of AIDS and SIVE. Quantitative PCR of FACS-sorted monocytes demonstrated a population of activated CD14highCD16low cells that were consistently SIV DNA positive. Additional animals underwent combination antiretroviral therapy (CART) immediately after significant decreases in NAA/creatinine (NAA/Cr) were measured by MRS. In CART animals, a rapid reversal of the decrease in NAA/Cr was found by 2 weeks after treatment, and the NAA/Cr ratios further returned to near preinfection levels by 4 weeks. CART led to a nominal decrease in plasma virus (100- to 1,000-fold), but significant inhibition of activated, SIV-infected monocytes was observed in non-CART animals that developed AIDS in the same period. Significantly, CART resulted in decreased monocyte infection by SIV. These data demonstrate the utility of a CD8 lymphocyte depletion model of neuroAIDS and MRS to study CNS pathogenesis and neuronal injury and underscore the role of the peripheral immune system in activated monocytes in contributing to CNS disease. FACS sorting and PCR analysis show that activated CD14highCD16low monocytes immunophenotypically similar to CNS perivascular macrophages are a probable cellular reservoir for SIV DNA and represent a “Trojan Horse” cell that can potentially carry virus to the CNS.

**Results**

These studies were performed in 2 parts. In the first series of experiments, we studied rhesus macaques that were SIV infected and CD8 lymphocyte depleted. In this series, MRS, PCR analysis for virus, flow cytometry, and FACS sorting for monocyte populations were performed for up to 8 weeks; animals were then euthanized, and histopathology assays were performed. In the second series, animals were SIV infected and CD8 lymphocyte depleted and subjected to the same assays described above, except these animals were treated with CART beginning at 28 days after infection so that the effects of decreased viral load and monocyte infection on neuronal injury could be studied.

**SIV infection and CD8 depletion induce CNS neuronal injury and encephalitis.** Six adult rhesus macaques were inoculated with SIVmac251 and CD8 lymphocyte depleted by administration of a CD8 lymphocyte–depleting antibody 6, 8, and 12 days after infection. Flow cytometry, MRI, and MRS were used to study peripheral monocyte activation and infection, plasma viral load, and neuronal injury during infection and AIDS. Flow cytometric analysis of peripheral blood and biopsied lymph nodes confirmed that all animals were persistently CD8+ T lymphocyte depleted (at least 28 days) (31) (Figure 1). Histopathological examination of biopsied lymph nodes did not show evidence of any pathology resulting from antibody treatment, consistent with previous studies (31, 32). Previous control studies of CD8 lymphocyte depletion without viral infection had shown that lymphoid tissues do not exhibit evidence of pathology (31, 32). The number of CD4+ T lymphocytes initially increased with CD8+ T lymphocyte depletion, beginning at day 7, and then decreased with the reemergence of CD8+ T lymphocytes between days 35 and 62. The absolute number of CD8+ T lymphocytes did not return to predemotion levels (Figure 1).

1H magnetic resonance spectra of frontal cortex, basal ganglia, and centrum semiovale were obtained, and NAA/Cr, choline/Cre (Cho/Cr), and myoinositol/Cre (MI/Cr) ratios calculated. Significant decreases in levels of the neuronal marker NAA, indicative of neuronal injury, were noted in all 3 brain regions of all animals following SIV infection and CD8 lymphocyte depletion. Decreases in NAA/Cr from preinfection time points to the onset of AIDS were easily detected, remarkably even by visual inspection (Figure 2, top panel). The decreases in NAA/Cr were more robust, with less animal-to-animal variation, than those observed in studies of SIV-mac251-infected animals that were not CD8 lymphocyte depleted.
SIVE, as defined by the presence of infiltrating perivascular inflammation, was present in all animals before or after infection. Microscopic, histopathological, and immunohistochemical examinations showed that all animals had SIVE, which peaked by 7–28 days after infection and remained elevated at later time points (Table 1). Plasma virus levels in all animals with survival times of 57, 63, 70, and 85 days after infection described above were euthanized when moribund with AIDS, before or after infection.

MRI images revealed no abnormality in any animal at any time point. Linear regression analysis revealed an inverse relationship between time of infection and NAA/Cr, Cho/Cr, and MI/Cr. The 19% decrease in NAA/Cr at several time points between SIV inoculation and onset of AIDS (Figure 2, bottom panel). Linear regression analysis revealed an inverse relationship between time of infection and NAA/Cr in the frontal cortex, basal ganglia, and the white matter. The 19% decrease in NAA/Cr in frontal gray matter and 14% decrease in white matter were revealed to be statistically significant ($P = 0.02$ and $P = 0.04$, respectively) by 2-tailed paired Student’s t tests. In contrast to the decreases in NAA/Cr, Cho/Cr, and MI/Cr did not change significantly over the course of infection (data not shown). Review of the MRI images revealed no abnormality in any animal at any time before or after infection.

The 4 SIVmac251-infected, CD8 lymphocyte–depleted animals described above were euthanized when moribund with AIDS, having survival times of 57, 63, 70, and 85 days after infection (mean, 69 days after infection). Plasma virus levels in all animals peaked by 7–28 days after infection and remained elevated at later time points (Table 1). Microscopic, histopathological, and immunohistochemical examinations showed that all animals had SIVE, as defined by the presence of infiltrating perivascular macrophages, MNGCs, and SIV-p27–positive, productively infected macrophages. The histopathology of these animals was similar to that of the most severe cases of SIVE we have observed in non–CD8 lymphocyte–depleted animals. Numerous cuffs of perivascular and inflammatory macrophages and MNGCs were found in virtually all brain sections examined. All sections had multiple lesions containing SIV-p27–positive, productively infected macrophages, damaged and injured neurons, white matter loss, and vacuolation (Figure 3). It is impossible to determine the exact timing of CNS pathologic changes, but neuronal injury was indicated by decreased NAA/Cr as early as 2 weeks after infection, occurring with an increased percentage of activated and infected blood monocytes (described below).

Postmortem neuronal assays confirm neuronal injury detected by MRS. Postmortem analysis of NAA/Cr by ex vivo MRS and quantitative immunohistochemical measurements of synaptophysin and microtubule-associated protein 2 (MAP-2) were performed to verify neuronal injury in the SIV-infected, CD8-depleted macaques. Frontal cortex samples from the 4 CD8 lymphocyte–depleted animals that were euthanized when they developed AIDS were evaluated and compared with frontal cortex samples from 4 control, non–CD8 lymphocyte–depleted animals. Three of 4 animals were scanned twice before infection, so there are 7 data points at time 0. All 4 animals were scanned at 2 weeks after infection. Three animals were scanned at 21 days and 3 were scanned at 40 days after infection. Thereafter, the animals were scanned at lower frequency. The measurements were derived from in vivo 1H MR spectra acquired from 1.5 × 1.5 × 1.5 cm3 voxels localized to the frontal lobe, centrum semiovale and basal ganglia. A strong linear relationship between the time of infection and the NAA/Cr ratio was present for frontal cortex within the frontal lobe ($r = -0.70; P = 0.0001$) (left), basal ganglia ($r = -0.57; P = 0.006$) (center), and centrum semiovale white matter ($r = -0.68; P = 0.0003$) (right).

### Table 1
Summary of SIV-infected, CD8-depleted rhesus macaques used in this study

<table>
<thead>
<tr>
<th>Animal no.</th>
<th>Duration of infection (d)</th>
<th>Duration of CD8 depletion (d)</th>
<th>CART</th>
<th>Plasma viral load (RNA copies/ml)</th>
<th>Histopathology</th>
</tr>
</thead>
<tbody>
<tr>
<td>169-90</td>
<td>85</td>
<td>26</td>
<td>None</td>
<td>$18 \times 10^6$</td>
<td>SIVE</td>
</tr>
<tr>
<td>169-94</td>
<td>70</td>
<td>40</td>
<td>None</td>
<td>$5 \times 10^6$</td>
<td>SIVE</td>
</tr>
<tr>
<td>217-93</td>
<td>57</td>
<td>26</td>
<td>None</td>
<td>$69 \times 10^6$</td>
<td>SIVE</td>
</tr>
<tr>
<td>224-93</td>
<td>63</td>
<td>33</td>
<td>None</td>
<td>$28 \times 10^6$</td>
<td>SIVE</td>
</tr>
<tr>
<td>166-93</td>
<td>57</td>
<td>26</td>
<td>Start 28 days after infection</td>
<td>$32 \times 10^6$</td>
<td>P.V. infiltrates</td>
</tr>
<tr>
<td>213-92</td>
<td>57</td>
<td>33</td>
<td>Start 28 days after infection</td>
<td>$24 \times 10^6$</td>
<td>Scattered inflammatory cells</td>
</tr>
</tbody>
</table>

*Non-CART animals with AIDS were moribund with disease at the time of necropsy; CART animals without AIDS were healthy at the time of sacrifice.

*Plasma viral load determined by real-time PCR showing peak value of data collected earlier than 28 days after infection and data collected at 34 days after infection, which was the next time point tested. n.d., not determined; P.V. infiltrates, perivascular infiltrates.
uninfected macaques. The in vivo NAA/Cr ratio in the frontal cortex of animals in the experimental group before SIV infection was the same as that of the control group (control, 1.29 ± 0.03; experimental, 1.29 ± 0.04). Ex vivo 1H MRS measurements of brain extracts from both groups of animals demonstrated a lower NAA/Cr ratio (P < 0.0005) in the SIV-infected, CD8-depleted animals (Figure 4). Quantitative immunohistochemical analysis revealed lower levels of synaptophysin (P < 0.004) in the SIV-infected, CD8 lymphocyte–depleted animals and a trend toward a decrease in MAP-2 (P < 0.09) (Figure 4). The observations of reduced levels of synaptic (synaptophysin) and dendritic (MAP-2) neuronal proteins were consistent with increased neuronal injury as shown by diminished NAA/Cr in vivo and ex vivo and by pathologic examination.

The degree of monocyte activation and infection correlates with CNS neuronal injury. Flow cytometry was used to measure changes in the percentage of CD14 monocytes and monocyte subpopulations and to sort populations for analysis of SIV RNA and DNA (Figure 5). These studies showed an increase in the percentage of CD14+ monocytes that coexpressed CD16. The percentage of these cells in blood initially increased 7–14 days after infection coincident with initial decreases in CNS NAA/Cr (Figure 6A). Increases in the absolute number or the percentage of CD14+ and CD14+CD16+ monocytes have been reported in HIV-infected humans and SIV-infected monkeys (8, 36–38). Such increases in CD14+ and CD16-positive monocyte populations are considered predictive of the incidence of HAD (6, 8), although longitudinal analyses of their expansion and direct correlation with neuronal injury have not been performed. In addition to the increased percentage of CD14+ blood monocytes that coexpressed CD16, we also found an increase in the percentage of blood monocytes characterized by low CD14 and high CD16 expression (CD14lowCD16high) (Figure 5). When analyzing either monocyte population, we found an increase in the percentage of cells after infection and then another increase prior to or with the onset of AIDS. To establish the timing and contribution of monocyte infection to CNS disease, we FACS sorted subsets of monocytes with varying levels of CD14 and CD16 using gates represented in Figure 5B. These subsets were selected because they are discreet and nonoverlapping populations that could be separated by FACS sorting. Quantitative PCR revealed early peaks in both RNA and DNA levels between 7 and 21 days after infection. This peak decreased after 21 days and then increased a second time with or prior to the development of AIDS (Figure 6, B and C). While neither subset exclusively harbored SIV RNA or DNA, the CD14lowCD16high population was consistently SIV RNA positive, above the detection limit of the assay, in all animals. These observations, along with the earlier suggestion that CD14+CD16+ monocytes also traffic to noninflamed tissues (12, 39) underscore the possibility that these cells function as a cellular reservoir of SIV DNA.

The number of plasma virions per milliliter in CD8 lymphocyte-depleted animals peaked 7–14 days after infection and remained elevated. Interestingly, this peak level of plasma virus corresponded with the initial decrease in NAA/Cr in the frontal cortex, basal ganglia, and white matter in all 4 animals, which continued to decrease as a function of time after infection (Figure 7A). In contrast to

Figure 3
Histopathological examination reveals inflammation, MNGCs, and neuronal injury in SIV-infected and CD8 lymphocyte–depleted monkeys. Photomicrograph of representative H&E (A and B), cresyl violet (C and D), and MAP-2 (E and F) micrographs demonstrate inflammation and degenerative changes in cortical neurons of CD8-depleted rhesus compared with uninfected controls. The H&E micrograph demonstrates extensive perivascular infiltrates and large cells with multiple nuclei in the CD8-depleted rhesus (B), while no evidence of infiltrates is seen in the uninfected control (A). The cresyl violet micrograph of the CD8-depleted animal (D) reveals severe cortical neuronal damage characterized by pyknotic nuclei as well as morphologic alterations of shrunken and angular cortical neurons compared with that of the control (C). Further evidence of neuronal injury is demonstrated by markedly decreased immunohistochemical expression of MAP-2 in neuronal processes in CD8-depleted rhesus (F) compared with uninfected control (E). Scale bar: 25

Figure 4
Neuronal injury in the frontal cortex of SIV-infected, CD8 lymphocyte–depleted rhesus macaques demonstrated by decreased synaptophysin and MAP-2 protein expression and decreased NAA/Cr analyzed in ex vivo tissues. Shown are measurements of synaptophysin (SYN), MAP-2, and NAA/Cr in the frontal cortex tissues from controls (black bars) and SIV infected, CD8 lymphocyte–depleted monkeys (white bars). The values are normalized to those for controls, which were considered to be 100%. Error bars represent SEM. P values determined by Student’s t test indicated significant or nearly significant differences between the control versus SIV-infected and CD8 lymphocyte–depleted monkeys.
the level of plasma virus, which peaked early after infection and remained elevated, the percentage of CD14-positive and CD16-positive monocytes increased twice: initially with peak viremia and then with AIDS (Figure 6). These observations suggest that plasma virus and/or activated monocytes contribute to neuronal injury.

**CART diminishes subsequent monocyte infection and activation.** To further study the role of plasma virus and/or activated monocytes contributing to neuronal injury, we initiated CART on 2 SIV-infected, CD8 lymphocyte–depleted animals at day 28 after infection. As in the previous experiment, these animals were persistently CD8+ T lymphocyte depleted (for more than 28 days) (Figure 1). Plasma virus in these animals dropped 100- to 1,000-fold immediately following (R)-9-(2-phosphonylmethoxypropyl) adenine (PMPA) and racemic β-2′,3′-dideoxy-5-fluoro-3′-thiacytidine (RCV) treatment on day 28 after infection (Figure 7A). SIV RNA and DNA levels also decreased in the CSF (data not shown). Paralleling changes in plasma virus levels, SIV RNA and DNA levels decreased in the CD14- and CD16-positive monocyte populations after initiation of CART (Figure 7, B and C). The percentage of CD14 monocytes coexpressing CD16 and activated CD14 low CD16 high monocytes was increased during primary infection, prior to initiation of CART (Figure 8). However, unlike the non-CART animals that had a second increase in the percentage of CD14 and CD16 monocytes, CART animals did not (Figure 8). More important, we did not detect subsequent increases in monocyte-associated SIV RNA or DNA levels in CART animals, though, again, the CD14 low CD16 high population was unequivocally identified as SIV DNA positive (Figure 8).

**Figure 5**
Analysis and acquisition gates for activated monocytes following SIV infection and CD8 lymphocyte depletion. (A) Representative flow cytometric analysis gates for activated CD14-positive monocytes that coexpressed CD16 (blue box) and CD14 low and CD16 high monocytes (red box). (B) FACS-sorted CD14 high CD16 high and CD14 low CD16 high monocyte populations from SIV-infected, CD8 lymphocyte–depleted rhesus macaques. Peripheral monocytes were initially identified based on forward scatter–versus-side scatter (FSC-versus-SSC) profiles of PBMCs (left panel). Contaminating CD3-APC+ T lymphocytes were gated out of the monocyte population (middle panel). CD14 high CD16 high and CD14 low CD16 high monocyte acquisition gates were set (right panel), and 5 × 10⁴ to 3 × 10⁵ cells per monocyte population were sorted.

**Figure 6**
Expansion of monocyte populations following SIV infection and CD8 lymphocyte depletion and analysis of monocyte-associated SIV RNA and DNA. (A) The percentage of monocytes that coexpressed CD16 was assayed as a function of time after infection. Two populations of activated monocytes were assessed: CD14+ monocytes that coexpressed CD16 (CD14+CD16+), and CD14 low CD16 high monocytes. Peaks in the percentage of both populations were observed between 7 and 14 days after infection. A second increase in the percentage of both populations was observed prior to or with the development of AIDS. **P < 0.05 and *P < 0.1 vs. day 0; paired Student’s t test. (B) SIV RNA was assessed in FACS-sorted populations of CD14 high CD16 high and CD14 low CD16 high monocytes. In both populations, there was an initial peak in the level of SIV RNA between 7 and 14 days after infection, followed by a decline and a subsequent increase prior to or coincident with the development of AIDS. (C) SIV DNA was assessed in FACS-sorted populations of CD14 high CD16 high and CD14 low CD16 high monocytes. In both populations, there was a peak in the level of SIV DNA 7–14 days after infection and another peak with the development of AIDS. The CD14 low CD16 high population was consistently SIV DNA positive. The hatched line represents the lower detection limit of the PCR assay.
Neuronal injury in SIV neuropathogenesis is rapidly reversed with CART. MRS showed that NAA/Cr decreased in both animals following CD8 depletion and SIV infection, prior to initiation of CART. At 28 days after infection, NAA/Cr ratios decreased to 89% and 81% of preinfection levels (Figure 9). Directly after MRS at day 28 after infection, CART commenced. After 2 weeks of CART, MRS revealed a reversal of the decrease in NAA/Cr in both animals (Figure 9). After 4 weeks of antiretroviral therapy, NAA/Cr completely recovered in one animal and increased from 81% to 93% of normal, preinfection levels in the other. Previous studies in SIV-infected macaques have confirmed that PMPA does not penetrate into the CNS (40). Of the nucleoside analogs, RCV has one of the lowest CNS penetrations (41). HPLC analysis of RCV metabolites in the CSF following treatment showed no penetration into the CSF.

Histopathologic and immunohistochemical examination of CNS tissues from CART animals demonstrated that neither had SIVE, and in fact they had few inflammatory cells. The animal that did not have a complete recovery of NAA/Cr to prescan levels had scattered accumulations of CD68- and CD16-positive perivascular macrophages, while the other animal did not (Figure 10). Tissue sections from both animals showed no evidence of SIV-p27, which indicated a lack of detectable productive infection as assessed by immunohistochemistry. We did not assay for SIV DNA or RNA and thus did not assess latent infection. These data are in stark contrast to those for non-CART animals, which had significant decreases in NAA/Cr and severe SIVE at the time of sacrifice. Non-CART animals had MNGCs and easily detectable SIV-p27 viral load in all brain sections examined. It is interesting to note that both the antiretrovirus-treated and nontreated animals were persistently CD8+ T lymphocyte depleted and had no or low absolute numbers of CD8+ T cells at death. Overall, these observations suggest that activated monocyte and macrophage accumulation in the CNS are indicators of and likely contributors to CNS neuronal injury.

Discussion

In this study, we examined CNS neuronal injury in a rhesus macaque model of neuroAIDS. In order to longitudinally assess mechanisms of neuronal injury in vivo during accelerated SIVE development, we used 1H MRS to monitor plasma virus and monocyte activation lev-
els in SIV-infected, CD8 lymphocyte–depleted macaques. Decreases in NAA/Cr in vivo occurred with initial activation and infection of monocytes in blood and macrophage accumulation; decreased NAA, MAP-2, and synaptophysin levels were observed in the CNS in postmortem assays. CART resulted in a rapid and significant reversal of decreased NAA levels, even though plasma and monocyte-associate SIV DNA and RNA levels decreased modestly. CART animals did not develop SIVE, and they had few CNS lesions and no detectable SIV protein as assessed by immunohistochemistry. These observations point to differences in neuropathology that are attributable to changes in peripheral blood virus levels and, more significantly, activation of peripheral monocytes and accumulation of monocytes/macrophages in the CNS.

We used MRS to monitor neuronal injury in vivo at several time points to study the role of plasma virus and activated and infected monocytes in neuropathology. The role of NAA as a reliable, noninvasive MRS neuronal marker has been confirmed by a large number of published studies (42, 43). We have previously reported direct, linear relationships between the number of neurons and NAA/Cr in postmortem Alzheimer and Pick disease brains (35, 42). Moreover, we have recently found that transient changes in NAA/Cr best correlated with changes in synaptophysin levels during acute SIV infection in the macaque (43). 1H MRS has been widely used to study HIV-infected patients, and early studies reported profound decreases in NAA/Cr (24, 44–48); such drops are less dramatic in the current highly active antiretroviral therapy (HAART) era. Improvement in NAA/Cr, along with neurocognitive improvement, has been reported following treatment with HAART (22, 25), which parallels the effect of treatment in the model reported here. Still, a recent multicenter study reported an 8% decrease in NAA/Cr in the centrum semiovale in patients undergoing HAART compared with controls (49).

Our studies demonstrate an expansion of CD14- and CD16-positive monocyte populations that others have described in HIV infection. We have extended these observations, pointing to a role of plasma virus and/or monocyte activation outside the CNS in neuronal injury. These monocytes are similar immunophenotypically and biologically to CNS perivascular macrophages that we and others have demonstrated are a major cell type productively infected by SIV and HIV in the CNS (9, 50–53). Several groups have reported that a unique phenotypic subset of activated monocytes is expanded in the blood of HIV-infected patients (10, 11, 54, 55). Early studies showed an increased frequency of CD14 monocytes that coexpressed CD16 (10, 11). Pulliam et al. reported a strong correlation between the incidence of HAD and the percentage of CD14-positive monocytes that coexpress CD16 and/or CD69 (8). The accumulation of perivascular macrophages in the brain as well as of macrophages of a similar immune phenotype in the lung correlates with the histopathology of CNS and lung (56, 57).

**Figure 9**
CART results in the rapid reversal of neuronal injury in SIV-infected, CD8 lymphocyte–depleted monkeys. NAA/Cr ratios in the frontal cortex (FC) of 2 SIV-infected, CD8 lymphocyte–depleted animals decreased to 89% and 81% of preinfection levels by 28 days after infection (open circles). Immediately after the MRS analysis on day 28, CART was initiated. Two weeks following CART, MRS revealed reversal of NAA/Cr in both animals. After 4 weeks of CART, one animal had a complete recovery of NAA/Cr, while the levels in the other animal increased from 81% to 93% of preinfection values. For comparison, NAA/Cr ratios in the frontal lobe of SIV-infected animals and CD8 lymphocyte–depleted animals that were not on CART, as shown in Figure 1, are also presented here (filled squares).

**Figure 10**
CART animals have no evidence of productive SIV infection and minimal inflammatory macrophages in the brain. Immunohistochemical characterization of lesions in SIVmac251-infected CD8-depleted untreated and CD8-depleted PMPA- and RCV-treated rhesus macaques. CD68 (KP1)–immunopositive perivascular macrophages in representative cerebral white matter samples from CD8-depleted untreated (A), CD8-depleted treated (B), and uninfected control animals (C). CD16-immunopositive activated perivascular macrophages and microglia in CD8-depleted untreated (D), CD8-depleted treated (E), and uninfected control animals (F). SIV-infected cells immunopositive for SIV-p27 in CD8-depleted untreated (G), CD8-depleted treated (H), and uninfected control animals (I). These data demonstrate a significant number of inflammatory macrophages and productive infection of the CNS in CD8 lymphocyte–depleted animals. In contrast, there were minimal inflammatory macrophages and no evidence of productive viral replication in CD8 lymphocyte–depleted monkeys that received PMPA and RCV. Data presented here are representative of 4 SIV-infected, CD8 lymphocyte–depleted animals; 2 SIV-infected, CD8 lymphocyte–depleted animals on CART; and 2 noninfected controls.
All animals were housed according to the Journal of Clinical Investigation. The occurrence of immune system dysfunction as indicated by loss of monkeys and humans, the development of AIDS and CNS disease in HIV-infected humans with CNS disease. In non–CD8-depleted animals and results from the CD8 depletion model represent a compression of the normal time frame seen in non–CD8-depleted animals and their degree of activation and infection and accumulation in the CNS. CART slightly decreased the plasma virus level, which was sufficient to decrease subsequent monocyte activation and, importantly, decrease monocyte-associated SIV RNA and DNA.

The results of our study using CART are in accordance with a recent report by Fox et al. (40). In these studies, neurophysiologic abnormalities measured during chronic SIV infection were reversed following PMPA treatment. However, Fox et al. did not use MRS and were thus unable to demonstrate a neuronal correlate of their neurophysiology readings (40). Interestingly, in Fox’s study, monocyte chemotactic protein–1 (MCP-1), a chemokine that regulates monocyte traffic to the CNS, was increased in the CSF upon primary infection and when animals developed AIDS. These observations are similar to those in HIV-infected humans, in whom elevated chemokine levels in the CSF correlate with neuronal injury. Taken together, these observations suggest that (a) neuronal injury in this model is reversible and (b) neuronal injury is likely dependent upon systemic viral replication, monocyte activation, or both. It is important to note that the partial inhibition of viral replication in the periphery was sufficient to rescue CNS neurons from injury. Taken together, these observations suggest that the immune system controls the regulation of the development of both AIDS and encephalitis and that activated monocytes, previously recognized as a surrogate marker of HAD, likely drive neuroAIDS progression.

Methods

SIV inoculation and CD8 depletion. All animals were housed according to the standards of the American Association for Accreditation of Laboratory Animal Care. Investigators abided by the Guide for the Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources (National Research Council). The study was approved by the Massachusetts General Hospital Subcommittee on Research and Animal Care and the Institutional Animal Care and Use Committee of Harvard University. Six rhesus macaques (Macaca mulatta) were inoculated with SIVmac251 (20 ng SIV-p27, i.v.). To achieve rapid disease progression with a high incidence of SIVE, all infected animals were CD8 lymphocyte depleted by treatment with an anti-CD8 antibody cM-T807 administered s.c. (10 mg/kg) at day 6 after infection and i.v. (5 mg/kg) at days 8 and 12 after infection (31, 32). This protocol resulted in rapid CD8 T lymphocyte depletion that was transient (~21 days) in approximately 50% of animals and persistent (>28 days) in 50%. More than 95% of persistently CD8 T lymphocyte-depleted animals develop AIDS and SIVE (33). The anti-CD8 mAb cM-T807 recognizes the CD8α chain that is present on CD3+CD8 T lymphocytes and CD4 and CD8 lymphocyte function and dysregulated, activated monocytes/macrophages (3, 64, 65). Several studies have recently used PMPA and RCV in SIV pathogenesis models (66–70). To date, there are no reports that treatment with either of these agents directly inhibits cellular immune responses. In this regard, the relative numbers of CD4+ and CD8+ T lymphocytes in our PMPA/RCV-treated versus nontreated animals were similar, which suggests that there was no effect of drug treatment on the percentage of lymphocytes in the blood.

It is important to note that several studies have suggested a role of immune responses in controlling the development of SIVE and HIV encephalitis (2, 40, 71). CD8+ T lymphocytes, many of which are potentially SIV antigen specific, have been demonstrated in the CNS of animals early after infection and terminally, where they are thought to play a role in viral containment and also neuronal injury (17, 72). Because all of the animals in our study were CD8+ T lymphocyte depleted when brain imaging occurred, it is possible that additional neuronal injury might have occurred with a full CD8 T cell component. Last, it has been suggested that CD8 lymphocytes regulate the expression of SIV RNA and protein in the CNS of infected animals (34). While such mechanisms likely occur, it is interesting that in the 2 PMPA- and RCV-treated animals, we did not detect SIV-p27 in the CNS, despite the presence of CD8+ T lymphocytes. These observations suggest that in our model, a continuous reseeding of virus from monocytes is required for CNS infection.

The present study used an SIV infection and CD8 lymphocyte depletion protocol in macaques to reproducibly induce CNS injury. Our results show that CART abolishes the expansion of activated monocyte populations and can almost completely reverse neuronal injury in the CNS, although its antiretroviral effect is confined in the periphery. These observations suggest that (a) neuronal injury in this model is reversible and (b) neuronal injury is likely dependent upon systemic viral replication, monocyte activation, or both. It is important to note that the partial inhibition of viral replication in the periphery was sufficient to rescue CNS neurons from injury. Taken together, these observations suggest that the immune system controls the regulation of the development of both AIDS and encephalitis and that activated monocytes, which did not have a second wave of activated CD14+ and CD16+ monocytes, decreased NAA/Cr, or macrophage accumulation in the CNS. It has been speculated that the neurologic benefits of HAART, reported in previous studies, were due to immune system modulation (61, 62). Our observation that macrophage accumulation in the CNS correlates with decreased NAA/Cr parallels observations of macrophage accumulation and paralysis in EAE. In the animal model of multiple sclerosis, macrophage and T lymphocyte accumulation is rapid, occurring days after active and passive immunization, and coincident with the induction of paralysis. Once inflammation wanes, in a matter of days, macrophages are no longer detected in the CNS, and paralysis resolves. In the case of SIV and HIV, viral infection or loss of neurons from injury. Taken together, these observations suggest that the immune system controls the regulation of the development of both AIDS and encephalitis and that activated monocytes, previously recognized as a surrogate marker of HAD, likely drive neuroAIDS progression.
Four animals were euthanized when they developed AIDS (ranging from 57–85 days after infection). Two animals that underwent CART were euthanized 2 weeks after initiation of treatment. Four noninfected controls were used for ex vivo MRS analysis and histopathology. All animals were anesthetized with ketamine-HCl, euthanized by intravenous pentobarbital overdose, and exsanguinated. CNS tissues were collected in 10% neutral buffered formalin, embedded in paraffin, and sectioned at 6 µm.

Postmortem neuronal assays. Quantitative immunohistochemistry on frontal cortex tissues and high-resolution ¹H MRS of brain extracts from the same region were used to evaluate the neuronal status of 4 SIV-infected, 2 SIV lymphocyte-depleted macaques that were not on CART and 4 non-SIV-infected controls at the time of euthanasia. These experimental animals were compared with 4 healthy, noninfected controls.

Ex vivo MRS. We performed ex vivo MRS to assess changes in NAA/Cr on brain tissues from 4 SIV-infected, 2 SIV lymphocyte-depleted animals and 4 non-SIV-infected controls to confirm in vivo experiments. For this, brain tissue was extracted using methanol/chloroform as previously described (80) modified for small samples using the FastRNA Green/ Biopulverizing System 1 (Qiogene Inc.) and a FastPrep FP 120 cell disrupter (Thermo Electron Corp.). Extracts were dissolved in D₂O, and ¹H NMR studies were performed on a Bruker Avance 600 MHz spectrometer (Bruker Instruments Inc.). A 1-pulse experiment was used with spectral acquisition parameters including a 90° pulse length of 9 µs, recycle delays of 20 seconds, a spectral width of 7.2 kHz, 32,000 complex points, and 64 scans, which were averaged. All spectra were processed off-line with the Peak Research NMR Software spectral analysis program (PERCH Solution version 2000/1; PERCH Solutions Ltd.).

Quantitative immunohistochemistry. The integrity of neuronal synapses was evaluated with a mAb against synaptophysin (Boehringer Mannheim), and the status of neuronal dendrites was evaluated using a mAb against MAP-2 (Boehringer Mannheim). Synaptophysin is a 38-kd calcium-binding protein localized to synaptic vesicles (81) and has been implicated in synaptic formation or stabilization (82). Synaptophysin is commonly used to assess synaptic density (83–87). MAP-2 is a high-molecular-weight protein that localizes to the dendritic compartment of neurons and is involved in microtubule assembly. Five-micron-thick paraffin sections from the frontal cortex of both control and SIV-infected macaques were immunolabeled as previously described (84, 86, 88). Levels of synaptophysin and MAP-2 were measured by computer-aided image analysis utilizing the Quantimet 570C microdensitometer (84, 88, 89). For this purpose, 3 immunolabeled sections from each animal were analyzed. The system was first calibrated with a set of filters of various densities, and a total of 10 images at ×100 magnification was obtained for each section. The area of interest (cortical layers 2–5) was delineated with the cursor, and then the optical density between the time of infection and the metabolite values. T1-weighted, proton density, and T2-weighted images were reviewed by a neuroradiologist to control for structural or signal abnormalities.

CART. To investigate the role of plasma virus and monocyte activation/infection in CNS neuronal injury, we treated 2 SIV-infected, CD8 lymphocyte-depleted animals with CART beginning 28 days after infection, once we had confirmed by MRS significant decreases in NAA/Cr. CART consisted of treatment with PMPA and RCV (75, 76). PMPA is a nucleotide analog that does not penetrate the CNS, and RCV is a nucleoside analog of a class that has low-to-nondetectable CNS penetration (40, 77–79). PMPA and RCV were dissolved in water at 30 mg/ml and the RCV pH adjusted to 7.0 with 3 N NaOH. Animals received daily injections of PMPA (30 mg/kg) and RCV (10 mg/kg) s.c. Plasma and CSF specimens taken before and after initiation of CART were stored at −80°C, and RCV metabolites were analyzed by HPLC, as previously described (76).

Tissue collection and processing. Four animals were euthanized when they developed AIDS (ranging from 57–85 days after infection). Two animals that underwent CART were euthanized 2 weeks after initiation of treatment. Four noninfected controls were used for ex vivo MRS analysis and histopathology. All animals were anesthetized with ketamine-HCl, euthanized by intravenous pentobarbital overdose, and exsanguinated. CNS tissues were collected in 10% neutral buffered formalin, embedded in paraffin, and sectioned at 6 µm.
within that area were determined. The optical density in each image was averaged and expressed as the mean per animal.

Flow cytometry and FACS-sorted monocyte populations. Five to 20 million Ficoll-Hypaque-separated PBMCs isolated from SIV-infected monkeys were stained with FITC-conjugated anti-CD14 (clone M5E2; BD Biosciences — Pharmingen), PE-conjugated anti-CD16 (3G8; BD Biosciences — Pharmingen), and APC-conjugated anti-CD3 (FN18; BioSource International). Cell sorting was done using a FACS Vantage (BD) flow cytometer in a Biosafety Level 2 facility. Monocyte populations were acquired using forward-versus-side scatter profiles and an acquisition gate (Figure 5B, left panel), and CD3- T lymphocytes were excluded by a second acquisition gate (Figure 5B, middle panel). Monocytes were fractionated based on CD14 and CD16 expression. For this and in order to best separate different populations of cells expressing CD14 and CD16, sorting gates for CD14(+)CD16(+) and CD14(-)CD16(+) monocyte populations were established (Figure 5A). Sorted cells were washed and rapidly snap-frozen for SIV DNA and RNA analysis, as described below. The purity of all FACS-sorted populations was confirmed by flow cytometry and was routinely greater than 95%.

Plasma and CSF SIV RNA. Plasma and CSF SIV RNA were quantified using real-time PCR as previously described (68). SIV virions were pelleted from 0.5 ml of plasma or CSF by centrifugation at 20,000 × g for 1 hour. The fluorescently labeled, real-time PCR probe employed contained a nonfluorescent quencher, BHQ-1 (Biosearch Technologies Inc.), at its 3’ end instead of the fluorescent quencher TAMRA (6-carboxy-tetramethyl-rhodamine). The threshold sensitivity was 100 copy Eq/ml, with an average interassay coefficient of variation of less than 25%.

Cell-associated SIV RNA and DNA. Total nucleic acids from FACS-sorted cell pellets with defined cell numbers were prepared. Pellets were suspended in 50 µl 3 M guanidine hydrochloride, 50 mM Tris, pH 7.6, containing 1 mg proteinase K/ml and incubated at 37°C for 1 hour. Two hundred microliters of 5.5 M (minimum) guanidine thiocyanate, 50 mM Tris, pH 7.6, 1 mM EDTA containing 600 µg glycogen/ml were added and samples mixed. Total nucleic acids were recovered by isopropanol precipitation and the pellets washed in 70% ethanol, air dried, and dissolved in 60 µl RNase-free water. Samples were split into 2 aliquots for separate DNA and RNA real-time PCR assays. For RNA assays, aliquots were treated with DNase, utilizing the DNA-free kit (Ambion Inc.) to remove any SIV-DNA-specific signals. To each sample, 6 µl of 10 DNA-free buffer was first added and the samples briefly mixed. Thirty-three microliters were then removed to a separate tube to which 2 µl DNasel and 5 µl inactivation reagent were added following the recommendations and protocol of the manufacturer to remove contaminating DNA signal and in preparation of the sample for measurement of SIV RNA equivalents. The reserved 33 µl of sample was heated to 100°C for 5 minutes and then quenched on ice, in preparation for measurement of SIV DNA equivalents. Quantification of SIV RNA, SIV DNA, and gene sequences for porphobilinogen deaminase (90), a single-copy genomic sequence used to determine diploid genome equivalents present in the final, prepared DNA sample, was performed as previously described (66). The results were normalized for volume adjustments and are expressed as SIV copy equivalent/10⁶ diploid genome equivalents.

Identification of brain macrophages and SIV-infected cells. Routine single-label immunohistochemistry was performed on formalin-fixed sections of frontal cortex using anti-CD16 (1:160; Novocastra) and anti-CD68 (1:400; KP1; DakoCytomation) and for productively infected cells using anti-SIV-p27 (3F7; American Biotech) as previously described (51).

Acknowledgments

We thank Angela Carville and Elisabeth Ludlage for animal care at the New England Primate Research Center; Eric Broadbent and Ernest Neale for veterinary technical assistance; Elizabeth Curran and Mike O’Connell for pathology support; and Kristen Toohey for photographic assistance. This work was supported in part by grants from the NIH, including National Center for Research Resources (NCRR) RR13214 (to R.G. González) and RR001050 (to S. Westmoreland); National Institute of Neurological Diseases and Stroke NS34626 (to R.G. González), NS0050041 (to R.G. González and K. Williams), and NS40237 (to K. Williams); and National Institute of Mental Health MH45294 (to E. Masliah). The NEPRC is supported in part through NCRR grant RR00168. The CD8 lymphocyte–depleting mAb used in this work was produced by the National Cell Culture Center with funds provided by NCRR grant RR16001. R.F. Shinazi is supported by Emory University Center for AIDS Research NIH grant 2P30-AI-50409 and the Department of Veterans Affairs. The Center for Functional Imaging Technologies at the Massachusetts General Hospital is supported by NCRR grant RR14075.

Received for publication August 5, 2004, and accepted in revised form June 14, 2005.

Address correspondence to: Kenneth Williams, Viral Pathogenesis, RE113 Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, Massachusetts 02215, USA. Phone: (617) 667-2064; Fax: (617) 667-8210; E-mail: Kenneth_Williams@hms.harvard.edu. Or to: R. Gilberto González, Neuroradiology Division, GRB 285, Massachusetts General Hospital, 55 Street, Boston, Massachusetts 02114, USA. Phone: (617) 726-8628; Fax: (617) 724-3338; E-mail: rggonzalez@partners.org.